Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24033583 | 0.87 | POLB (0.42) | POLBSMN1; SMN2ALDH1A1ALOX15MAPK1 | |
| SCHEMBL24033595 | 0.76 | POLB (0.35) | POLBSMN1; SMN2ALDH1A1ALOX15MAPK1 | |
| SCHEMBL24034153 | 0.76 | POLB (0.32) | POLBSMN1; SMN2 | |
| SCHEMBL27010647 | 0.75 | ALDH1A1 (0.50) | ALDH1A1ALOX15MAPK1 | |
| SCHEMBL24033581 | 0.73 | KDM1A (0.35) | POLBSMN1; SMN2 | |
| SCHEMBL1121836 | 0.67 | NOTUM (0.35) | POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL4675449 | 0.66 | POLB (0.40) | POLBSMN1; SMN2 | |
| SCHEMBL761956 | 0.66 | CYP11B1 (0.35) | POLBSMN1; SMN2MAPK1 | |
| SCHEMBL30343506 | 0.66 | POLB (0.39) | POLBSMN1; SMN2 | |
| SCHEMBL24034155 | 0.66 | POLB (0.39) | POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295135-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295135-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11591322-B2 | Certain chemical compositions and methods of use thereof | ALGEN BIOTECHNOLOGIES, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2021231892-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591322-B2 | Certain chemical compositions and methods of use thereof | CDK9, CDK19, CDK6 | POLB 612/4885SMN1; SMN2 330/4885ALDH1A1 1530/4885 |
| US-20230295135-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | CDK9, CDK19, CDK6 | POLB 612/4885SMN1; SMN2 330/4885ALDH1A1 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.